Anti-cd30l antibodies and uses thereof
US-2024254246-A1 · Aug 1, 2024 · US
Neutralization of CD95 activity blocks invasion of glioblastoma cells in vivo
US9309320B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9309320-B2 |
| Application number | US-52162507-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 28, 2007 |
| Priority date | Dec 28, 2006 |
| Publication date | Apr 12, 2016 |
| Grant date | Apr 12, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating an individual with high grade glioma, comprising administering an agent that neutralizes CD95 activity to an individual with high grade glioma, wherein said agent is a CD95 ligand (CD95L) inhibitor comprising a fusion protein comprising the extracellular domain of CD95 and a human Fc domain. 2. The method of claim 1 , wherein the fusion protein is a fusion protein of the extracellular domain of the human CD95 with human IgG1-Fc (APG101). 3. The method of claim 1 , wherein the high grade glioma is a WHO Grade III or IV glioma. 4. The method of claim 1 , wherein the high grade glioma is a WHO Grade IV glioma. 5. The method of claim 1 , wherein an interaction between CD95 and the protein p85 of PI3K is inhibited. 6. The method according to of claim 1 , wherein said agent is administered in an amount sufficient to reduce glial cell migration and/or invasion.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
of other specific parts of the body, e.g. brain · CPC title
- C07K16/2875Primary
against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154 (against NGF C07K16/22, against TNF C07K16/241) · CPC title
NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95 · CPC title
Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9309320B2 cover?
- The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.
- Who is the assignee on this patent?
- Martin-Villalba Ana, Kleber Susanne, Wiestler Benedikt, and 5 more
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2875. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).